Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy?

Jürgen Götz; Lars M. Ittner; Nicole Schonrock

Alzheimer's disease and frontotemporal dementia

prospects of a tailored therapy?

Jürgen Götz^*, Lars M. Ittner, Nicole Schonrock

^*Corresponding author for this work

Research output: Contribution to journal › Article

25 Citations (Scopus)

Abstract

• Alzheimer's disease (AD) is the most prevalent dementia (accounting for 50%-75% of cases of dementia in people aged over 65 years), followed by frontotemporal dementia (FTD) (10%-20% of cases).

• AD is characterised histopathologically by Aβ-containing amyloid plaques and tau-containing neurofibrillary tangles, whereas FTD exhibits neurofibrillary tangles alone.

• Current symptomatic treatments of AD are of limited benefit, as they are not directed at the underlying biological basis of the disease.

• The development of transgenic animal models has provided insight into disease mechanisms and helped define novel drug targets.

• More than 50 drugs are currently in clinical trials, and novel and more effective drugs targeting both AD and FTD are expected to become available within 5-10 years.

Original language	English
Pages (from-to)	381-384
Number of pages	4
Journal	Medical Journal of Australia
Volume	185
Issue number	7
Publication status	Published - 2 Oct 2006
Externally published	Yes

Access to Document

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy?'. Together they form a unique fingerprint.

Cite this

Götz, J., Ittner, L. M., & Schonrock, N. (2006). Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy? Medical Journal of Australia, 185(7), 381-384.

@article{876d4c2974af48afa7a9e3e8265c59f1,

title = "Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy?",

abstract = "• Alzheimer's disease (AD) is the most prevalent dementia (accounting for 50{\%}-75{\%} of cases of dementia in people aged over 65 years), followed by frontotemporal dementia (FTD) (10{\%}-20{\%} of cases). • AD is characterised histopathologically by Aβ-containing amyloid plaques and tau-containing neurofibrillary tangles, whereas FTD exhibits neurofibrillary tangles alone.• Current symptomatic treatments of AD are of limited benefit, as they are not directed at the underlying biological basis of the disease. • The development of transgenic animal models has provided insight into disease mechanisms and helped define novel drug targets. • More than 50 drugs are currently in clinical trials, and novel and more effective drugs targeting both AD and FTD are expected to become available within 5-10 years.",

author = "J{\"u}rgen G{\"o}tz and Ittner, {Lars M.} and Nicole Schonrock",

year = "2006",

month = "10",

day = "2",

language = "English",

volume = "185",

pages = "381--384",

journal = "Medical Journal of Australia",

issn = "1326-5377",

publisher = "Wiley-Blackwell, Wiley",

number = "7",

}

TY - JOUR

T1 - Alzheimer's disease and frontotemporal dementia

T2 - prospects of a tailored therapy?

AU - Götz, Jürgen

AU - Ittner, Lars M.

AU - Schonrock, Nicole

PY - 2006/10/2

Y1 - 2006/10/2

N2 - • Alzheimer's disease (AD) is the most prevalent dementia (accounting for 50%-75% of cases of dementia in people aged over 65 years), followed by frontotemporal dementia (FTD) (10%-20% of cases). • AD is characterised histopathologically by Aβ-containing amyloid plaques and tau-containing neurofibrillary tangles, whereas FTD exhibits neurofibrillary tangles alone.• Current symptomatic treatments of AD are of limited benefit, as they are not directed at the underlying biological basis of the disease. • The development of transgenic animal models has provided insight into disease mechanisms and helped define novel drug targets. • More than 50 drugs are currently in clinical trials, and novel and more effective drugs targeting both AD and FTD are expected to become available within 5-10 years.

AB - • Alzheimer's disease (AD) is the most prevalent dementia (accounting for 50%-75% of cases of dementia in people aged over 65 years), followed by frontotemporal dementia (FTD) (10%-20% of cases). • AD is characterised histopathologically by Aβ-containing amyloid plaques and tau-containing neurofibrillary tangles, whereas FTD exhibits neurofibrillary tangles alone.• Current symptomatic treatments of AD are of limited benefit, as they are not directed at the underlying biological basis of the disease. • The development of transgenic animal models has provided insight into disease mechanisms and helped define novel drug targets. • More than 50 drugs are currently in clinical trials, and novel and more effective drugs targeting both AD and FTD are expected to become available within 5-10 years.

UR - http://www.scopus.com/inward/record.url?scp=33749596351&partnerID=8YFLogxK

M3 - Article

VL - 185

SP - 381

EP - 384

JO - Medical Journal of Australia

JF - Medical Journal of Australia

SN - 1326-5377

IS - 7

ER -